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Abstract 43 
Importance: Steroid 5α-reductase type 3 congenital disorder of glycosylation (SRD5A3-CDG) is a rare 44 
disorder of N-linked glycosylation.  The retinal phenotype is not well described and could be 45 
important for disease recognition since it appears to be a consistent primary presenting feature. 46 
Objective: To investigate a series of patients with the same steroid 5α-reductase type 3 (SRD5A3) 47 
mutation thereby characterising the retinal manifestations and other associated features. 48 
Design, setting and participants: Seven affected individuals from four unrelated families presenting 49 
with early-onset retinal dystrophy (EORD) as a primary manifestation underwent comprehensive 50 
ophthalmic assessment, including retinal imaging and electrodiagnostic (EDT) testing.  51 
Developmental and systemic findings were also recorded.  Molecular genetic approaches including 52 
target-enrichment NGS, autozygosity mapping and apex microarray, were used to try and reach a 53 
diagnosis; all were mutation negative. Whole exome (WES) or whole genome sequencing (WGS) was 54 
used to identify the causative variant.  Biochemical profiling was conducted to confirm a CDG Type I 55 
defect.  56 
Main outcome measures: Detailed clinical phenotypes, genetic and biochemical results. 57 
Results: The mean age of participants at their most recent exam was 17.1 years (SD 3.9), all were of 58 
South Asian ethnicity and 71.4% of the cohort was female.  WES and WGS identified the same 59 
homozygous SRD5A3 c.57G>A, p.(Trp19Ter) variant as the underlying cause of EORD in each family.  60 
Detailed ocular phenotyping identified early-onset (≤3 years of age) visual loss (mean BCVA = +0.95 61 
LogMar (SD: 0.34)), childhood-onset nyctalopia, myopia (mean refractive error -6.71 (SD-4.22)) and 62 
nystagmus. Six of seven patients had learning difficulties and psychomotor delay.  Fundus 63 
autofluorescence imaging and optical coherence tomography scans were abnormal in all patients, 64 
and EDT revealed rod and cone dysfunction in the five patients tested. 65 
Conclusions and relevance: These data suggest mutations in SRD5A3 cause EORD, a previously 66 
under-described feature of SRD5A3-CDG that is progressive and may lead to serious visual 67 
impairment.  SRD5A3 and other glycosylation disorder genes should be considered as a cause of 68 
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retinal dystrophy even where systemic features are mild.  Further delineation of SRD5A3 associated 69 
eye phenotypes can help inform genetic counselling for prognostic estimation of visual loss and 70 
disease progression. 71 
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Text 72 
Congenital disorders of glycosylation (CDG) are a large group of neurometabolic diseases caused by 73 
impaired glycoconjugate synthesis.  Type I CDGs (CDG-I), result from disruptions in the early N-linked 74 
glycosylation pathway1.  Numerous CDG-I sub-types exist that are characterised by neurological, 75 
developmental, hepatic and coagulation abnormalities, alongside ocular, muscular, skeletal, 76 
dermatological, cardiovascular, or genitourinary involvement in some forms.1,2  Approximately 23 77 
different genes have been associated with this group of disorders.1  Steroid 5α-reductase type 3 78 
(SRD5A3, MIM 611715) encodes a polyprenol reductase enzyme required for the synthesis of 79 
dolichol, the end product of the mevalonate pathway.3  Dolichol undergoes phosphorylation to 80 
produce dolichol phosphate that serves as the lipid-anchor for N-glycan biosynthesis in the 81 
endoplasmic reticulum.3   82 
Biallelic mutations in SRD5A3 cause SRD5A3-CDG (formerly known as CDG-Iq; MIM 612379), a 83 
phenotypically variable form of CDG-I that features nystagmus, optic atrophy, visual loss, muscle 84 
hypotonia, intellectual disability and cerebellar ataxia. 3,4  Biochemically, SRD5A3-CDG is 85 
characterised by a transferrin isoelectric focusing (TIEF) pattern that is typical of CDG-I.5  Defective 86 
glycan synthesis results in altered sialotransferrin forms, detectable by charge differences and 87 
characterized by increased di- and/or asialotransferrin in cases of CDG-I.5 Kahrizi syndrome, 88 
featuring iris coloboma, juvenile cataract, contractures, kyphosis, mental retardation, motor delay 89 
and lack of speech (MIM 612713), has also been reported in association with biallelic variants in 90 
SRD5A3.6  Patients described thus far, have considerable phenotypic overlap with SRD5A3-CDG, 91 
though demonstrate a normal TIEF profile.6,7  Unlike other CDG-I subtypes, all patients with SRD5A3-92 
CDG develop abnormal ocular phenotypes and almost always experience early-onset visual loss, 93 
such that the ocular presentation can be an early and obvious disease-delineating feature.  94 
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Previous studies of this disorder focus on genetic findings in relation to the neurometabolic and 95 
developmental manifestations of the condition, with only one study having acknowledged a retinal 96 
abnormality.8  Hence, the appearance, onset and progression of the SRD5A3-CDG-related retinal 97 
phenotype is poorly understood.  We report detailed ocular and developmental phenotypes in seven 98 
individuals with early-onset retinal dystrophy (EORD), from four unrelated families who were found 99 
to harbour the same SRD5A3 mutation via whole exome (WES) or whole genome sequencing (WGS).   100 
Methods 101 
Clinical Assessment 102 
Study participants were ascertained from Manchester Centre for Genomic Medicine (Manchester, 103 
England), Moorfields Eye Hospital (London, England) and St James’s University Hospital (Leeds, 104 
England).  The Northwest Research Ethics Committee granted approval for all aspects of this study 105 
(11/NW/0421 and 15/YH/0365) and the protocol observed the tenets of the Declaration of Helsinki.  106 
Written informed consent was obtained from each study participant, or parental consent was 107 
obtained on behalf children, as an essential pre-requisite for study inclusion. 108 
Each patient underwent full ophthalmic assessment including visual acuity and dilated fundus 109 
examination.  Fundus photographs were obtained using conventional 35o colour fundus photography 110 
(Topcon Great Britain, Ltd., Berkshire, UK) or Wide-field Optos™ colour fundus imaging (Optos plc, 111 
Dunfermlin, UK).  Fundus autofluorescence (FAF) imaging was conducted using either the 55o 112 
Spectralis (Heidelberg Engineering Ltd., Heidelberg, Germany) or ultra-widefield confocal scanning 113 
laser imaging (Optos™ plc, Dunfermlin, UK).  Optical coherence tomography (OCT) was performed 114 
using the Spectralis OCT platform (Heidelberg Engineering).  Five patients underwent 115 
electroretinography (ERG), three using gold foil electrodes and performed to standards specified by 116 
the International Society for Clinical Electrophysiology of Vision (ISCEV) and two using surface 117 
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electrodes.9,10  Developmental and dysmorphology assessments were conducted by a clinical 118 
geneticist or inherited metabolic disease specialist. 119 
Molecular Investigations 120 
Genetic Analysis 121 
Target-next generation sequencing (105 gene inherited retinal dystrophy panel testing and whole 122 
exome sequencing (WES)) was conducted as previously detailed by Arno et al. (2016).11   123 
Briefly: the proband of families I and III underwent screening for a panel of 105 known inherited 124 
retinal dystrophy (IRD) genes (described in O’Sullivan et al., 2012)12 at the Manchester Genomic 125 
Diagnostic Laboratory. Family II (GC15567) underwent SNP analysis using an Affymetrix 50k Xba SNP 126 
chip (Affymetrix Inc., Santa Clara, CA, USA) on DNA samples from the parents, one affected and two 127 
unaffected children to identify regions of homozygosity in the affected child for the prioritization of 128 
candidate genes.  The proband from family IV was screened using a commercially available apex 129 
microarray for 344 published disease-causing variants in eight genes associated with Lebers 130 
congenital amaurosis (LCA) and EORD (Asper Ophthalmics, Tartu, Estonia).  The proband from family 131 
I-III underwent WES as part of an ongoing study of inherited retinal disease in families without a 132 
molecular diagnosis following targeted gene panel screening (UK Inherited Retinal Disease 133 
Consortium, UKIRDC).   134 
The affected individual and unaffected parents of family IV underwent whole genome sequencing 135 
(WGS) as part of the 100,000 Genomes Project. Briefly, genomic DNA was processed using the 136 
Illumina TruSeq DNA PCR-Free Sample Preparation kit (Illumina Inc) and sequenced using an Illumina 137 
HiSeq X Ten, generating minimum coverage of 15X for >97% of the callable autosomal genome.  138 
Reads were aligned to build GRCh37 of the human genome using the Isaac aligner (Illumina Inc). 139 
SNVs and indels were identified using Platypus v0.8.1 and annotated using Cellbase 140 
(https://github.com/opencb/cellbase).  Variant filtering was performed using MAF in publicly 141 
available and in-house datasets, predicted protein impact and familial segregation. Surviving variants 142 
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were prioritized using two prespecified virtual gene panels from PanelApp 143 
(https://bioinfo.extge.co.uk/crowdsourcing/PanelApp/): Intellectual disability v1.2, which includes 144 
SRD5A3, and Posterior segment abnormalities v1.7. Allelic state was required to match the curated 145 
mode of inheritance for variants in panel genes. 146 
The SRD5A3 c.57G>A p.Trp19Ter homozygous variant (GenBank accession NM_024592) was 147 
confirmed by Sanger sequencing using BigDye Terminator v3.1 Cycle Sequencing Kit (Applied 148 
Biosystems Corporation, Foster City, Ca, USA). 149 
Biochemical Studies 150 
Where samples were made available, Type I N-glycosylation defect was confirmed using isoelectric 151 
focussing of serum transferrin and blood coagulation studies.5 152 
Results 153 
Patient Phenotypes 154 
The mean age of participants at their most recent exam was 17.1 years (SD 3.9), all were of South 155 
Asian ethnicity and 71.4% of the cohort was female.  Phenotypes are summarized in Table 1. 156 
Family I 157 
Family I, originally from India, had a history of consanguinity and no prior family history of health 158 
problems. 159 
The proband, patient I.I, from family I (G40001, Figure 1) was born slightly under-weight at 6lbs and 160 
was mildly jaundiced after birth. A developmental and dysmorphology assessment by a clinical 161 
geneticist found only mild developmental delay.  She walked at 18 months and developed speech at 162 
the normal time.  She attended mainstream school where she received assistance because of her 163 
visual problems, but was able to complete the same level of work as her peers. 164 
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At five weeks of age she was not fixing and following but was otherwise well.  At the age of 5 years, 165 
ophthalmic review identified a decline in visual acuity; fundus imaging and electrophysiological 166 
testing led to a preliminary diagnosis of CSNB (Table 1 and Figure 2).  At her latest visit at 20 years of 167 
age, right and left best-corrected visual acuity (BCVA) measured 1.5 Logmar (20/800 Snellen 168 
equivalent) with a mild myopic refractive error (Table 1).  Fundus autofluoresence (FAF) imaging was 169 
also abnormal (Figure 2). 170 
Patient I.II was born at term following an uneventful pregnancy and was otherwise fit and well.  At 171 
five years of age, she was described as being hyperactive with an attention deficit and suffering from 172 
frequent sleep disturbances.  At age 7 years, examination by a clinical geneticist diagnosed a social 173 
communication disorder, behavioural problems and learning difficulties.  Dysmorphology 174 
assessment identified thick hair, thick gums, coarse facies and slender, tapered fingers.   175 
Aged 2 months, I.II presented with multi-planar nystagmus.  On examination, she was found to be 176 
mildly myopic, while fundoscopy revealed only attenuated retinal blood vessels and ERG 177 
demonstrated no recordable response in the dark (Figure 2 and Table 1).  FAF at 3 years was also 178 
abnormal (Figure 2).  At age 7 years, she began to report symptoms of nyctalopia. 179 
  Family II 180 
The proband (II.I) and her affected sister (II.I) from family II (GC15567, Figure 1) were born to first 181 
cousin parents of a family originating from Gujarat, India.   182 
Examination of patient II.I by a clinical geneticist found delayed motor and speech development 183 
with associated learning difficulties at young age.  She was found to have variable manifest 184 
nystagmus and myopia at age 18 months.  At five years of age, her BCVA measured 3/12 single Kays 185 
(0.60 logMAR equivalent; 20/80 Snellen equivalent) in the right and left (Table1).  Electrodiagnostic 186 
testing at the age of 11 years identified both rod and cone system dysfunction.  In her second 187 
decade she became symptomatic with nyctalopia and photophobia.  Funduscopic, FAF and OCT 188 
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examinations identified multiple abnormalities indicative of retinitis pigmentosa (RP) (Table 1, Figure 189 
2 and Figure 3). 190 
Patient II.II was reviewed by a paediatrician aged 18 months and found to have normal muscle tone 191 
but increased, brisk reflexes and mild hyperkeratosis on the right leg.  She also had developmental 192 
delay and learning difficulties with normal growth parameters, with a normal skeletal survey.  She is 193 
particularly anxious and has a very short memory.  194 
II.II was found to have pendular nystagmus and roving eye movements at 3 months of age.  195 
Electrodiagnostic testing at the age of 7 years suggested rod and cone dysfunction.  By the age of 15 196 
years her myopia increased and she was experiencing poor night vision and photophobia.  Fundus, 197 
FAF and OCT examinations were abnormal and indicative of RP in the absence of pigmentary 198 
changes (Table 1, Figure 2 and Figure 3). 199 
  Family III 200 
The affected sibling pair from family III (LDS3659, Figure 1) were born to apparently non-201 
consanguineous parents originating from India. 202 
Patient III.I experienced learning difficulties from a young age and was described as having a slightly 203 
‘clumsy’ walking style.  She was noticed to have poor visual behaviour, by her family within the first 204 
year of life.  A myopic refractive error was detected at 18 months, which progressed to high myopia 205 
by the age of 16 years (Table 1).  Examination of the fundus, by colour and FAF imaging, revealed 206 
abnormalities suggestive of retinal pigment epithelium (RPE) malfunction (Table 1 and Figure 2).  207 
OCT scans were corroborative of this and indicated loss of outer segment structures with complete 208 
loss of photoreceptor layer (Figure 3). 209 
11 
 
Patient III.II, when examined aged 14 years, was found to have an ataxic gait and reduced upper 210 
limb co-ordination- both signs of mild cerebellar disease.  He also demonstrated global 211 
developmental delay and experienced recurrent respiratory tract infections.   212 
He experienced loss of vision with associated roving eye movements between two and three years 213 
of age.  He also presented with early-onset nyctalopia and high myopia (Table 1).  Ophthalmic 214 
examination revealed abnormalities similar to those of his brother apart from a small region of 215 
photoreceptor preservation within the central macular (Table 1 and Figure 3).   216 
Family IV 217 
The proband (IV.I) from family IV, a male, was born to apparently non-consanguineous parents 218 
originating from India (GC15063, Figure 1).  Examination of patient IV.I at 4.5 years of age identified 219 
developmental delay, learning difficulties and abnormal curvature of the spine (Table 1).  220 
Ophthalmic history revealed infantile-onset nystagmus and reduced vision.  At 4.5 years, he was 221 
found to have reduced visual acuity (0.60 logMAR RE and LE) and myopia (Table 1).  At his most 222 
recent examination at 24 years of age, his vision had deteriorated (Table 1) and fundus exam 223 
revealed retinal vessel attenuation and pale optic discs (Figure 1).  ERG indicated both rod and cone 224 
dysfunction (Table 1) and OCT scan revealed loss of outer segments structures with relative 225 
preservation of the central macular, bilaterally (Figure 3). 226 
Molecular Analysis 227 
Clinically available genetic testing did not identify any potentially pathogenic variants in 105 known 228 
retinal dystrophy genes in the proband of families I and III.  Autozygosity mapping and candidate 229 
gene sequencing did not identify any pathogenic variants in the proband of family II.  Apex array 230 
analysis in patient IV.I was also mutation negative.  Subsequent WES or WGS led to the identification 231 
of SRD5A3 c.57G>A, p.(Trp19Ter) homozygous variant in each proband.  Sanger sequencing 232 
confirmed the presence and zygosity of this variant in every affected member of each family. The 233 
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SRD5A3 p.(Trp19Ter) variant has an allele frequency of 0.001174 in 4684 controls of South Asian 234 
ethnicity, according to the ExAC dataset.  In homozygous state, this same variant has been described 235 
as the cause of SRD5A3-CDG in four unrelated families.4,8,13 236 
Both siblings from family III underwent screening for biochemical abnormalities that may be 237 
associated with congenital disorders of glycosylation.5 Mild abnormalities of blood clotting (activated 238 
partial thromboplastin time (APTT) 43.6s, APTT ratio 1.4) and a microcytic hypochromic blood profile 239 
were observed in both. Liver function tests were normal, however, a CDG type I pattern of 240 
transferrin glycoforms was observed. 241 
Discussion 242 
Biallelic mutations in SRD5A3 cause SRD5A3-CDG (CDG-Iq; MIM612379) a phenotypically variable 243 
disorder of N-linked glycosylation that is normally characterised by neuro-developmental 244 
abnormalities and ophthalmic manifestations.3,4  We report seven patients from four families with a 245 
retinopathy consequent upon the SRD5A3 p.(Trp19Ter) mutation.  This mutation has been reported 246 
to cause SRD5A3-CDG previously, in four unrelated families.4,8,13  Our case series provides an in-247 
depth description of the ocular symptomology and appearance over the course of ophthalmic 248 
follow-up.  The retinopathy, unlike the extra-ocular features of this disease, appears to be slowly 249 
progressive.  On fundal view, signs of retinal disease may be very subtle and bone spicules absent in 250 
young patients.  Likewise, syndromic manifestations associated with mutation of SRD5A3 may also 251 
be very mild.  This detailed description of retinal phenotype could be important for early disease 252 
recognition since it appears to be a consistent primary presenting feature.Early-onset visual loss (≤ 3 253 
years of age, mean BCVA = +0.95 LogMar (SD= 0.34)) and nystagmus are consistent manifestations 254 
associated with the SRD5A3 p.(Trp19Ter) variant in this cohort of seven patients.  Other shared 255 
ocular findings were: retinal arteriolar attenuation in the absence of bone spicule formation (n=7), 256 
childhood-onset nyctalopia (n=5) and optic disc pallor (n=5).  Each of the patients reported in this 257 
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series also experienced varying degrees of progressive myopia (mean refractive error -6.71 (SD= 258 
4.22)), ranging from relatively mild to high (Table 1).  None of our patients were either 259 
microphthalmic, nor did they have ocular colobomata as has been described in association with 260 
other SRD5A3 mutations.4  Mutual systemic associations included learning difficulties and 261 
developmental delay.  One patient was found to have only mild developmental delay as a young 262 
child (<5 years of age), which may have been attributable to her severe visual impairment since she 263 
went on to meet normal developmental and intellectual milestones with increasing age.   264 
Despite the absence of a pigmentary retinopathy, widespread loss of outer retinal structures was 265 
evidenced by OCT, with relative preservation of foveal photoreceptors, and only mild epiretinal 266 
membrane formation (Figure 3).  Electroretinography, where performed (n=5), identified 267 
dysfunction in both rod and cone pathways at the level of the photoreceptor allowing discrimination 268 
from disorders involving the photoreceptor-bipolar cell synapse, such as CSNB, as three out of seven 269 
patients here initially received a clinical diagnosis of CSNB.  Previous reports of patients with SRD5A3 270 
mutations have not described OCT findings.  There has been a single description of retinal bone 271 
spicule pigmentation in an adult sibling pair with the SRD5A3 p.(Trp19Ter) variant.  Due to lack of 272 
previous descriptions of RP as a feature of SRD5A3-CDG, Kara et al., 2014 hypothesized that it may 273 
be a late onset feature of the condition.8  Our findings suggest that the onset of retinal degeneration 274 
is likely to occur in childhood in at least a proportion of cases and indeed, ocular imaging and FAF do 275 
suggest early dysfunction of the RPE. 276 
Rhodopsin is a pigment containing, G protein-coupled receptor that is expressed in rod 277 
photoreceptors cells where it specifically localises to the rod outer segments (ROS)14.  Studies have 278 
shown that the N-terminus of rhodopsin contains two N-linked glycosylation sequences.15  279 
Mutations at glycosylated amino acid residues or surrounding glycosylation consensus sequences of 280 
rhodopsin cause autosomal dominant and sectoral RP in humans.16,17  Studies in animal models 281 
expressing non-glycosylated rhodopsin have shown that although the mutant proteins undergo 282 
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normal biosynthesis, folding and trafficking, they confer toxicity, causing rod cell death, leading to 283 
light-sensitive retinal degeneration.18  Evidence on whether non-glycosylated rhodopsin incorporates 284 
into and initiates disk morphogenesis in ROS is conflicting.19,20  It is possible that the SRD5A3 285 
p.(Trp19Ter) variant prevents normal glycosylation of rhodopsin in the retina and subsequently 286 
impairs its normal incorporation and/or function in the ROS, thereby leading to defective 287 
phototransduction and loss of vision, before eventual photoreceptor death and the presentation of 288 
RP.  Similarly, non-glycosylation of other retinal proteins such as ABCA4, known to have seven N-289 
glycosylation sites, could also lead to defective phototransduction, and eventual cell death.21  This is 290 
an area that warrants further research.  291 
The SRD5A3 p.(Trp19Ter) variant has a frequency of 0.0012 in the South Asian population according 292 
to the ExAC dataset- a frequency that is 30 times higher than other ethnic groups, suggesting that 293 
this is an ancestral variant within this specific population.  Further, findings from our cohort suggest 294 
that phenotypic subtleties mean this condition goes unrecognised or unsuspected.  Alongside recent 295 
evidence for a role of other glycosylation disorder genes in non-syndromic retinal dystrophy 296 
(POMGNT122 and DHDDS23), we suggest that CDG genes should be considered in clinical diagnostic 297 
gene panels for retinal disease.   298 
Conclusions 299 
This case series is the first to provide a detailed account of the retinal dystrophy consequent upon 300 
the p.(Trp19Ter) mutation in SRD5A3, delineating the complex phenotype associated with SRD5A3-301 
CDG. Furthermore, we illustrate the wide variability in onset and progression of the disorder in 302 
patients with the same null mutation.  We report EORD as a novel feature of SRD5A3-CDG and 303 
suggest that retinal degeneration without pigmentary change may be an early manifestation of CDG 304 
that may progress to RP over time.  Crucially, our findings also suggest that SRD5A3 may cause these 305 
ocular manifestations alongside only mild learning difficulties, in some instances, in contrast to the 306 
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neurodevelopmental delay and other systemic features usually associated with SRD5A3-CDG3,4.   Our 307 
work adds to cumulative evidence that NGS offers a proficient means of diagnosis for this genetically 308 
heterogeneous and phenotypically variable group of conditions.6,24,25  For CDG, precise diagnosis 309 
enables the provision of more accurate prognostic information regarding loss of vision and risk of 310 
later onset manifestations.  Better understanding of the pathogenesis of SRD5A3 mediated retinal 311 
disease could lead to the development of novel therapeutic strategies.  Findings in our cohort show 312 
that the macular, although non-functional, remains structurally intact making this condition a good 313 
target for gene therapy. 314 
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Table 1:  Ophthalmic and phenotypic presentations of patients with SRD5A3 p.(Trp19X) mutation 
Family (gender)/I.D number I.I (F)/G40001.1) I.II (F)/G40001.2 II.I (F)/GC15567.1 II.II (F)/GC15567.2 III.I (F)/LDS3659.1 III.II (M)/LDS3659.2 IV.I (M) 
Ethnicity South Asian South Asian Indian Indian Pakistani Pakistani Indian 
Age at onset 5w 2m 18m 3m <1y 2-3y <1y 
Age at last exam 20y 13y 18.5y 14.5y 16y 14y 24y 
Consanguinity    + +  - - 
Ophthalmic findings  
Ophthalmic history 
Failure to fix and follow, multi-
planar nystagmus, mild myopia 
from 2m, nyctalopia from 6y, 
initial diagnosis of CSNB made at 
6y 
Multi-planar nystagmus, 
strabismus, progressive 
myopia from 2m, nyctalopia 
from 7y 
Variable manifest nystagmus, 
squint, myopia from 18m 
Nystagmus and roving eye 
movements from 3m, myopia, 
poor night vision and photophobia 
Roving eye movements and 
nyctalopia from <1y, high myopia,  
exophoria decompensating into 
an exotropia from 16y, central 
scotomata 
Roving eye movements from 2-3y, 
nyctalopia, high myopia, exophoria 
Early-onset nystagmus and 
myopia 
BCVA (Snellen equivalent) 
[age] 
1.5 LogMar (20/640) RE and LE 
[20y] 
1.3 LogMar (20/400) RE and 
LE [7y] 
0.900  crowded LogMar 
(20/160) RE; 0.800 (20/125) 
crowded LogMar LE [6y] 1.0 LogMar (20/200) RE; 0.8 LogMar (20/125) LE [15y] Data not available 
0.6 LogMAR (20/80) RE and 
LE [4.5y] 
1.04 LogMar (20/250) RE; 1.20 
LogMar (20/320) LE [13y] 
0.72 LogMar (20/100) RE; 0.36 
LogMar (20/50) LE [18.5y] 
1.0 LogMAR (20/200) RE and 
LE [24y] 
Refractive error [age] RE:-1.00/+0.25x90; LE: -1.25/+0.25x80  [20y] 
-2.00/+1.00x100 RE; -
3.00/+1.00 x 80 LE [2m] 
-2.5/-2.5 x 180 RE; -1.5/-3.0 x 
170 LE [6y] 
-1.5/-1.25 x 180 RE; -2.00/-2.00 x 
180 LE [18m] -15.50/+0.25x109 RE; 
 -14.00/+1.00x92 LE [16y] 
-9.50/+1.50x103 RE,  
-8.25/+2.5x106 LE [14y] 
RE: -7.00/-0.75 x 180; LE: -
7.5DS [24y] -6.00/+1.75X90 RE and -
6.50/+1.00 x90 LE [3y] 
-3.00/-3.5 x 180 RE; -3.50/-4.0 
x 160 LE [18.5y] 
-5.5/-3.75x155 RE; -5.5/-3.75x100 
LE [15y] 
Fundus imaging 
Optic disc pallor, foveal 
hypoplasia, granular appearance 
of peripheral retina, attenuated 
retinal vasculature. 
Subtle temporal optic disc 
pallor, mildly attenuated 
retinal arterioles, prominent 
nerve fibre layer visible 
radiating around the superior 
and inferior vascular arcades. 
Patchy (RE) and stippled (LE) 
macular reflex. 
Tilted optic disc with temporal 
pallor, peri-papillary atrophy 
temporally, absence of foveal 
reflex (LE only), attenuated 
retinal vasculature. 
Myopic tilted discs, attenuated 
retinal vasculature, subtle 
mottling in the retinal periphery 
(data not shown) 
Myopic tilted discs, attenuated retinal vasculature, subtle mottling in the 
retinal periphery (data not shown) 
Optic disc pallor, attenuated 
retinal vasculature 
FAF Well defined ring of hyper-autofluorescence around the macula 
Diffuse ring of hyper-fluorescence 
at the periphery of the macular 
with normal autofluorescence 
centrally apart from a hyper-
autofluorescent dot at the fovea 
Diffuse ring of hyper-
autofluorescence around the 
macula 
Well defined ring of hyper-
autofluorescence around the macula 
(data not shown) 
Diffuse ring of hyper-
autofluorescence around the 
macula 
OCT Data not available 
Widespread loss of outer 
retinal structures with relative 
preservation of foveal 
structures including 
photoreceptors. 
Widespread loss of outer retinal 
structures with relative 
preservation of foveal structures 
including photoreceptors. 
Widespread loss of outer retinal 
structures and complete absence 
of the photoreceptor layer 
Widespread loss of outer retinal 
structures with relative preservation of 
foveal structures including 
photoreceptors. 
Widespread loss of outer 
retinal structures with 
relative preservation of 
foveal structures including 
photoreceptors. 
ERG (age at testing) Indicative of rod-cone dystrophy (no details available) (5y) 
Low amplitude light-adapted 
response, extinguished dark-
adapted response (2m) 
Undetectable rod-specific 
responses and delayed and 
subnormal cone-specific 
responses (11y) 
Limited compliance with test but 
reduced and delayed cone-specific 
responses found with rod 
involvement 
Data not available Data not available 
Profoundly electronegative 
ERG, and grossly delayed 
cone-specific responses 
Developmental/Neurological 
findings 
Mild developmental delay up to 
5 years of age 
Dysmorphic, communication 
and behavioural problems, 
learning difficulties, recurrent 
respiratory infections, gait 
ataxia. 
Psychomotor delay, learning 
difficulties 
Increased, brisk reflexes, 
psychomotor delay and learning 
difficulties 
Learning difficulties, gait ataxia, 
normal reflexes, mild upper limb 
co-ordination difficulties on 
finger-nose test. Normal height, 
weight and head circumference. 
Learning difficulties, developmental 
delay, gait ataxia, normal reflexes, mild 
upper limb co-ordination difficulties on 
finger-nose test. Recurrent respiratory 
infections. Normal height, weight and 
head circumference. 
Developmental delay, 
learning difficulties, scoliosis 
Other Investigations 
Urine organic acids (normal) 
Plasma phytanic acid levels 
(normal) 
Hearing assessment (normal); 
uMPS (normal); 
Oligosaccharides (normal); 
Lysosomal enzymes (normal); 
X-ray (normal); aCGH (normal) 
VLCFAs (normal) 
Lysosomal enzymes (normal) 
White cell and plasma 
enzymes (normal) 
VLCFAs (normal) 
Lysosomal enzymes (normal) 
White cell and plasma enzymes 
(normal) 
   
19 
 
n.d.: not disclosed; w: weeks; m: months; y: years; RE: right eye; LE: left eye;  ERG: electroretinography;  OCT: optical coherence tomography; FAF: fundus autofluoresence; uMPS: urine mucoplysaccharides; + present; - absent; DS: dioptre 
sphere; VLCFAs: very long chain fatty acids; aCGH: array comparative genomic hybridization
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Figure Legends 407 
Figure 1: Pedigrees of families (I-IV) included in this study.  Arrows indicate proband. 408 
 409 
Figure 2: Colour fundus and fundus autofluorescence (FAF) images of patients with SRD5A3 410 
p.(Trp19Ter) variant. a,c,e,g: Wide-field Optos™ colour fundus imaging;  i,k,m,o,q,s: 35° colour 411 
fundus photography; b,d,f,h,j,l,n,p,r: FAF imaging RE: right eye; LE: left eye; Y: years of age; RE: right 412 
eye; LE: Left eye, FAF: Fundus autofluoresence; AF: autofluorescence. 413 
 414 
Figure 3: Optical coherence tomography (OCT) in patients with SRD5A3 p.(Trp19Ter) variant. OCTs 415 
are shown as horizontal (a-e, g, h), or vertical (f) scans and accompanying en face infra-red image 416 
with location at which the scan through the macular was taken (indicated by green arrow). Arrow 417 
heads demarcate the transition of absent/present photoreceptors (except in c where part of the 418 
macular is not visible, and e where the photoreceptor layer is completely absent). RE: right eye; LE: 419 
left eye; Y: years of age. 420 
 421 



